Andrey V. GUDKOV
Senior Vice President for Basic Research,
Chair of the Department of Cell Stress Biology,
Roswell Park Cancer Institute (Buffalo, New York, USA)
PhD (oncology), DSc (biology)
Areas of expertise:
new principles, drugs and targets for the prevention and treatment of cancer; molecular and cellular targets and drugs in anti-aging medicine; origin and control of retroelements, their role in evolution and currently existing pathologies
Special awards and honors:
University Scholar, University of Illinois at Chicago (1999)
P. K. Ranney Foundation Award, Cleveland Clinic Foundation (2005)
Garman Family Chair in Cell Stress Biology, Roswell Park Cancer Institute (2008)
Thomas Tomasi Hope Award, Roswell Park Cancer Institute (2016)
Long before I reached the age of reason, I was thrilled by the mystery of living and nonliving objects. And I still am. Coupled with my passion and love for puzzles, this feeling drove me to become an experimental biologist. As a young scientist I was not interested in curing diseases and saw pathologies as hints to what a normal life really is. And then I (almost accidentally) got a position at the Department of Virology of MSU where I met absolutely brilliant teachers who taught me about viruses (Vadim Agol), immune system (Harry Abelev) and cancer (Yury Vasiliev). My entry ticket to big science was research on endogenous viruses that showed me patterns and mysteries of eukaryotic genome plasticity in evolution and cancer that I am still trying to solve. For a long time I was striving to find a key to a mystery of progressive evolution. Now that I have found it, I dream of writing a book. When working in America, I became interested in developing new drugs that could help us understand and test the mechanisms of life of the living organism. I learned a lot about the mechanisms of toxicity of anticancer drugs and radiation, came up with some ideas on how to protect the organism from their damaging effect without inhibiting their anticancer activity. Gradually I came to realize that it is not only malignancy as such that we should fight - we must also find a way to undermine its underlying cause, which is the mechanism of cell evolution. I believe I know how to do it. I dream of writing a book on the mechanisms of progressive evolution; I also want to prove that there is a permanent solution to cancer problem based on the inhibiting of its creative adaptivity, and I want to create a precursor of an anti-aging drug.
- Hall BM, Balan V, Gleiberman AS, Strom E, Krasnov P, Virtuoso LP, Rydkina E, Vujcic S, Balan K, Gitlin I, Leonova K, Polinsky A, Chernova OB, Gudkov AV. Aging of mice is associated with p16(Ink4a)- and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. Aging (Albany NY). 2016; 8 (7): 1294–315.
- Komarov AP, Komarova EA, Green K, Novototskaya LR, Baker PS, Eroshkin A, Osterman AL, Chenchick AA, Frangou C, Gudkov AV. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-dependent apoptosis that protect mice from acute liver failure. Cell Death Dis. 2016; 7: e2145.
- Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. PNAS. 2016 Feb 16; 113 (7): E874–83.
- Krivokrysenko VI, Toshkov I, Gleiberman AS, Krasnov P, Shyshynova I, Bespalov I, Maitra R, Narizhneva N, Singh VK, Whitnall M, Purmal A, Shakhov A, Gudkov AV, and Feinstein E. TLR5 Agonist Entolimod Mitigates Acute Radiation Syndrome in Non-human Primates. PLoS One. 2015; 10 (9): e0135388.
- Natarajan V, Komarov AP, Ippolito T, Bonneau K, Chenchik AA, Gudkov AV. Peptides genetically selected for NF-kB activation cooperate with oncogene Ras and model carcinogenic role of inflammation. PNAS. 2014; 111 (4): E474–83.
- Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova K, Gleiberman AS, Aygun-Sunar S, Veith J, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, Medvedev A, Scheblyakov D, Artemicheva NM, Logunov DY, Gintsburg AL, Naroditsky BS, Makarov SS, Gudkov AV. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonists. PNAS. 2013; 110 (20): E1857–66.
- Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, Sen GC, Komarova EA, Gudkov AV. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. PNAS. 2013; 110 (1): E89–98.
- Gorbunova V, Hine C, Tian X, Ablaeva J, Gudkov AV, Nevo E, Seluanov A. Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. PNAS. 2012; 109 (47): 19392–6.
- Spengler ML, Kuropatwinski KK, Comas-Soberats M, Gasparian AV, Fedtsova N, Gleiberman AS, Gitlin II, Artemicheva NM, Deluca KA, Gudkov AV, Antoch MP. Core circadian protein CLOCK is a positive regulator of NF-kB-mediated transcription. PNAS. 2012; 109 (37): E2457–65.
- Yoon S-I, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA. Structural Basis of TLR5-Flagellin Recognition and Signaling. Science. 2012; 335 (6070): 859–64.